These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26301220)

  • 1. Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K.
    Pallegar NK; Ayre DC; Christian SL
    Front Cell Dev Biol; 2015; 3():47. PubMed ID: 26301220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway.
    Woods D; Cherwinski H; Venetsanakos E; Bhat A; Gysin S; Humbert M; Bray PF; Saylor VL; McMahon M
    Mol Cell Biol; 2001 May; 21(9):3192-205. PubMed ID: 11287623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1.
    Lucas L; Penalva V; Ramírez de Molina A; Del Peso L; Lacal JC
    Int J Oncol; 2002 Sep; 21(3):477-85. PubMed ID: 12168089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase.
    McFall A; Ulkü A; Lambert QT; Kusa A; Rogers-Graham K; Der CJ
    Mol Cell Biol; 2001 Aug; 21(16):5488-99. PubMed ID: 11463831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways.
    Grana TM; Rusyn EV; Zhou H; Sartor CI; Cox AD
    Cancer Res; 2002 Jul; 62(14):4142-50. PubMed ID: 12124353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global gene analysis identifying genes commonly regulated by the Ras/Raf/MEK and type I IFN pathways.
    Komatsu Y; Hirasawa K; Christian SL
    Genom Data; 2015 Jun; 4():84-7. PubMed ID: 26484185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
    Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
    Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells.
    Ulkü AS; Schäfer R; Der CJ
    Mol Cancer Res; 2003 Dec; 1(14):1077-88. PubMed ID: 14707291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells.
    Hayes CS; DeFeo K; Lan L; Paul B; Sell C; Gilmour SK
    Oncogene; 2006 Mar; 25(10):1543-53. PubMed ID: 16278677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase.
    Lee J; Choi KJ; Lim MJ; Hong F; Choi TG; Tak E; Lee S; Kim YJ; Chang SG; Cho JM; Ha J; Kim SS
    Cell Res; 2010 Aug; 20(8):919-34. PubMed ID: 20603646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of oocyte maturation by jun-N-terminal kinase (JNK) on the oncogenic ras-p21 pathway is dependent on the raf-MEK signal transduction pathway.
    Chie L; Amar S; Kung HF; Lin MC; Chen H; Chung DL; Adler V; Ronai Z; Friedman FK; Robinson RC; Kovac C; Brandt-Rauf PW; Yamaizumi Z; Michl J; Pincus MR
    Cancer Chemother Pharmacol; 2000; 45(6):441-9. PubMed ID: 10854130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals.
    von Gise A; Lorenz P; Wellbrock C; Hemmings B; Berberich-Siebelt F; Rapp UR; Troppmair J
    Mol Cell Biol; 2001 Apr; 21(7):2324-36. PubMed ID: 11259582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
    Kanno E; Kawasaki O; Takahashi K; Takano K; Endo T
    Exp Cell Res; 2018 Jan; 362(1):111-120. PubMed ID: 29129563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor.
    Menges CW; McCance DJ
    Oncogene; 2008 May; 27(20):2934-40. PubMed ID: 18059341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
    Su CC
    Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.